Galapagos Adds Roche Veteran to Board Amid Strategic Pivot
Event summary
- Galapagos appointed Dr. Paulo Fontoura as Non-Executive Independent Director on February 9, 2026.
- Dr. Fontoura replaces Dr. Susanne Schaffert, who stepped down on November 1, 2025.
- Fontoura brings 20 years of pharmaceutical experience, including leadership roles at Roche and Xaira.
- His expertise spans neurology, immunology, ophthalmology, and rare diseases.
- Galapagos aims to leverage his experience for strategic guidance and business development.
The big picture
Galapagos' appointment of Dr. Paulo Fontoura reflects a strategic focus on disciplined growth and business development. Fontoura's extensive experience in clinical development and leadership roles at major pharmaceutical companies positions him to provide critical guidance as Galapagos evaluates its next phase of growth. This move aligns with broader industry trends of leveraging cross-functional expertise to drive innovation and value in the biopharmaceutical sector.
What we're watching
- Strategic Pivot
- How Fontoura's experience will shape Galapagos' approach to transformative business development opportunities.
- Clinical Development
- Whether Fontoura's background in digital health and clinical endpoints will accelerate Galapagos' pipeline advancements.
- Governance Dynamics
- The pace at which the new board composition will influence Galapagos' long-term value delivery for shareholders.